S ex differences in blood pressure (BP) and renal dysfunction in hypertension are well established. Men are more prone to develop hypertension and renal dysfunction than are premenopausal females of the same age. [1] [2] [3] Male and female animals show differences in BP and renal dysfunction in various models of hypertension, including angiotensin II (Ang II)-and deoxycorticosterone acetate salt-induced hypertension, and in Dahl salt-sensitive and spontaneously hypertensive rats. 4, 5 Males are most likely to develop hypertension and renal dysfunction compared with females in these models of hypertension.
S ex differences in blood pressure (BP) and renal dysfunction in hypertension are well established. Men are more prone to develop hypertension and renal dysfunction than are premenopausal females of the same age. [1] [2] [3] Male and female animals show differences in BP and renal dysfunction in various models of hypertension, including angiotensin II (Ang II)-and deoxycorticosterone acetate salt-induced hypertension, and in Dahl salt-sensitive and spontaneously hypertensive rats. 4, 5 Males are most likely to develop hypertension and renal dysfunction compared with females in these models of hypertension. [6] [7] [8] [9] Castration minimized and ovariectomy (OVX) enhanced Ang II-induced hypertension and caused renal dysfunction. [10] [11] [12] Recently, we reported that the cytochrome P450
(CYP) 1B1 contributes to Ang II-induced hypertension and associated pathophysiological changes in male mice by generating the testosterone metabolite 6β-hydroxytestosterone. 13, 14 In contrast, CYP1B1 was critical for protecting against Ang II-induced hypertension in female mice. 15 Cyp1b1 gene disruption or inhibition of CYP1B1 activity enhanced Ang IIinduced increase in systolic blood pressure (SBP) and renal dysfunction in female mice. 15, 16 CYP1B1 metabolizes 17-β estradiol into 2-hydroxyestradiol (2-OHE) and 4-hydroxyestradiol (4-OHE). 17 We showed that 2-OHE decreased, whereas 4-OHE enhanced, Ang II-induced increase in SBP in Cyp1b1 inhibited Ang II-induced increases in SBP in Cyp1b1 −/− mice. 15 Moreover, infusion of Ang II increased plasma and urinary levels of 2-ME in female Cyp1b1 +/+ mice but not in Cyp1b1 −/− mice, 15, 16 suggesting that 2-ME mediates the protective effect of estradiol against Ang II-induced hypertension. These observations raised the possibility that 2-ME protects against renal dysfunction and end-organ damage associated with enhanced Ang II-induced hypertension in Cyp1b1 −/− and gonadectomized female mice. To test this hypothesis, we examined whether replacement with 2-ME in intact female Cyp1b1 −/− mice or OVX Cyp1b1 +/+ and Cyp1b1 −/− mice attenuated Ang II-induced renal dysfunction and end-organ damage and whether it also attenuates Ang II-induced hypertension, renal dysfunction, and end-organ damage in male Cyp1b1 +/+ mice. Because Ang II-induced increase in urinary angiotensinogen (AGT) contributes to hypertension and its pathogenesis, 18 the effect of Ang II on urinary AGT levels in intact female and OVX Cyp1b1 +/+ and Cyp1b1 −/− mice and male Cyp1b1 +/+ mice and its modulation by 2-ME was also examined. These results show that 2-ME attenuates Ang II-induced increases in SBP, renal dysfunction, and end-organ damage in female Cyp1b1 −/− or OVX Cyp1b1 +/+ and Cyp1b1 −/− mice and in Cyp1b1 +/+ male mice.
Methods
All experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals under protocols approved by University of Tennessee Health Science Center Institutional Animal Care and Use Committee. Experiments were conducted on 8-to 10-week-old, 20-to 25-g body weight, intact Cyp1b1 −/− (C57BL/6 background) and OVXCyp1b1 +/+ (C57BL/6 background) and Cyp1b1 −/− female mice and Cyp1b1 +/+ male mice. Mice were infused with Ang II (700 ng/kg per minute) or saline (vehicle) for 14 days with subcutaneously implanted micro-osmotic pumps. In a different set of experiments, 2-ME (1.5 mg/kg IP every third day) was given alone and concurrently with Ang II infusion in both intact and OVX female mice and intact male mice. BP was measured using the noninvasive tail-cuff method every third day. Water intake, urine output, urinary osmolality, protein content, and electrolytes were determined. BP and metabolic data from intact Cyp1b1 +/+ male mice from previous studies 13, 15 were used to reduce the number of mice to comply with the 3R guidelines set by the Institutional Animal Care and Use Committee. Detailed experimental methods are available in the online-only Data Supplement. Figure 1A) . 15 In this study, we determined whether 2-ME restores protection against the enhanced pressor effect of Ang II in OVX Cyp1b1
Statistical Analysis
+/+ and Cyp1b1 −/− mice. Treatment with 2-ME did not alter basal BP but reduced the effect of Ang II on SBP in both OVX Cyp1b1 +/+ and Cyp1b1 −/− mice ( Figure 1B ) to levels observed in intact female mice. 15 
2-ME Minimizes Ang II-Induced Hypertension in Male Mice
Ang II increases SBP to a greater degree in Cyp1b1 +/+ compared with Cyp1b1 −/− male mice. 13 We investigated whether 2-ME, the nonfeminizing active metabolite of 17β-estradiol, attenuates the Ang II-induced increase in SBP in Cyp1b1 +/+ male mice. Infusion of Ang II increased SBP in male Cyp1b1 +/+ mice, and it was reduced by treatment with 2-ME; basal BP was not altered by 2-ME ( Figure 1C ). Figure 2 ). Ang II also increased Na + and K + excretion, which did not reach statistical significance as analyzed by 2-way analysis of variance; 2-ME treatment of intact Cyp1b1 −/− and OVX Cyp1b1
2-ME Minimizes
and Cyp1b1 −/− mice had no effect on Na + and K + excretion (Figures S1 and S2). 
2-ME Minimized

Male Mice
Ang II increased water intake and urine output and caused renal dysfunction in Cyp1b1 +/+ male mice. 14 Treatment with 2-ME in male Cyp1b1 +/+ mice decreased Ang II-induced increase in water intake, urine output, and proteinuria ( Figure  S3 ) but did not alter the decrease in osmolality or sodium and potassium excretion in male Cyp1b1 +/+ mice ( Figure S4 ). The values for Ang II alone and its vehicle used for comparison were derived from our previous study. 14 
2-ME Attenuates Ang II-Induced Renal Fibrosis in Intact Cyp1b1
−/− and OVX Female Mice 
2-ME Attenuates Ang II-Induced Cardiac and Renal Fibrosis in Male Cyp1b1 +/+ Mice
We have shown that Ang II increased cardiac and renal fibrosis in intact male Cyp1b1 +/+ mice, and Cyp1b1 gene disruption reduced cardiac and renal fibrosis in male mice. 13, 14 In this study, treatment with 2-ME inhibited Ang II-induced cardiac and renal fibrosis in male Cyp1b1 +/+ mice ( Figure S7 ).
2-ME Attenuates Ang II-Induced Increase in Urinary Excretion of AGT in Cyp1b1 −/− and OVX Female Mice but Not in Intact Male Mice
Ang II-induced production of renal AGT and generation of renal Ang II have been implicated in renal dysfunction and hypertension. 18, 19 Therefore, we determined if Cyp1b1 gene disruption and OVX increase urinary excretion of AGT and its modulation by 2-ME. Ang II did not alter the urinary excretion of AGT in Cyp1b1 +/+ female mice, but increased urinary excretion of AGT in intact Cyp1b1 −/− female mice; this increase was attenuated by treatment with 2-ME. Ang II also increased urinary excretion of AGT in OVX Cyp1b1 +/+ and Cyp1b1 −/− mice; this increase was inhibited by 2-ME ( Figure 3 ). In our earlier study, we showed that Ang II increased urinary excretion of AGT in male Cyp1b1 +/+ mice. 14 We investigated whether treatment with 2-ME decreases Ang II-induced increase in urinary excretion of AGT in male Cyp1b1 +/+ mice. Treatment with 2-ME did not alter the Ang II-induced increase in urinary excretion of AGT in male Cyp1b1 +/+ mice ( Figure 3 ). 
OVX Does Not Alter Renal Expression of ACE and
Cyp1b1
−/− mice, and treatment with 2-ME also did not alter ACE or AT1a mRNA expression in these animals infused with Ang II or its vehicle ( Figure S8 ).
2-ME Does Not Alter Renal mRNA Expression of AT1a Receptor and ACE in Male Mice
We reported that castration decreased renal expression of AT1a and ACE mRNA expression.
14 Here we examined whether 2-ME decreases renal AT1a and ACE mRNA expression in male Cyp1b1 +/+ mice. Infusion of Ang II or concurrent treatment with 2-ME did not alter the renal expression of AT1a or ACE mRNA expression in these mice ( Figure S9 ).
GPER1 Antagonist G15 Does Not Alter the Effect of Ang II on SBP and Water Intake or Urine Output in Intact Cyp1b1
+/+ Female Mice G protein-coupled receptor, namely GPER1 (previously known as GPR30), a novel estrogen receptor, is expressed in various tissues, and G1, a selective agonist of GPER1, reduces BP in both male Sprague-Dawley rats and, in high doses, in OVX mRen.Lewis female rats. 20 Because Ang II increases plasma and urinary levels of 2-ME in Cyp1b1 +/+ but not Cyp1b1 −/− female mice, 15, 16 we determined whether GPER1 contributes to Ang II-induced increase in SBP and urine and water output by examining the effect of G15, a selective GPER1 receptor antagonist, in Cyp1b1 +/+ female mice. Administration of G15 (40 μg; IP every third day) did not alter the effect of Ang II on SBP ( Figure S10A ), water intake, or urine output in Cyp1b1 +/+ female mice ( Figure S10B ); G15 alone reduced body weight, heart weight, and heart:body weight ratio but did not alter the effect of Ang II on heart:body weight ratio (Table S3) . −/− mice were OVX and infused with Ang II or vehicle for 14 days and treated with 2-ME. Mice were placed in metabolic cages on the 12th day of Ang II infusion and acclimated for 24 h. Water intake and urine output were measured on Day 14. Urine was analyzed for the parameters listed in Methods. n=5 for each group of experiments, and data are expressed as mean±SEM. *P<0.05 OVX+Ang II vs OVX.
Discussion
The main findings of this study are that 2-ME, a catechol-O-methyltransferase-derived metabolite of 2-OHE, which is generated by CYP1B1 from estradiol, inhibits Ang II-induced in female Cyp1b1 gene-disrupted or OVX mice. Previously, we reported that Cyp1b1 gene disruption or inhibition of CYP1B1 activity minimized the Ang II-induced increase in SBP, renal dysfunction, and end-organ damage in male mice. 13 In contrast, Cyp1b1 gene disruption or inhibition of CYP1B1 activity had the opposite effect in female mice. 15, 16 We also showed that 2-ME inhibited Ang II-induced increase in SBP in Cyp1b1 −/− mice, and infusion of Ang II increased plasma and urine levels of 2-ME in female Cyp1b1 +/+ mice but not in Cyp1b1 −/− mice. 15, 16 Peripheral administration of estradiol rescued male rats from deoxycorticosterone acetate salt-and Ang II-induced hypertension. 21 Moreover, 2-ME also prevented deoxycorticosterone acetate salt-induced hypertension in male rats 22 and attenuated hypertension, coronary vascular remodeling, and ischemia reperfusion injury in mice. 23, 24 In the present study, infusion of Ang II increased water intake and urine output, decreased urine osmolality, and caused marked proteinuria in Cyp1b1 −/− female mice. Our finding that the replacement with 2-ME minimized these effects of Ang II in Cyp1b1 −/− female mice suggests that 2-ME mediates the protective effect of estradiol against Ang II-induced renal dysfunction in female mice. Supporting this conclusion was our finding that Ang II in OVX Cyp1b1
and Cyp1b1 −/− mice increased water intake and urine output, decreased urine osmolality, and caused marked proteinuria, and treatment with 2-ME restored the protection against these effects and the increase in SBP produced by Ang II in these mice. The effect of 2-ME to inhibit Ang II-induced increase in water intake in Cyp1b1 −/− and OVX mice suggests that 2-ME most likely inhibits the central action of Ang II on thirst. We have shown that, in Cyp1b1 +/+ male mice, Ang II increased water intake, urine output, and Na + excretion, decreased urine osmolality, and caused marked proteinuria.
14 Our demonstration that treatment with 2-ME also reduced the effect of Ang II to increase water intake, urine output, and proteinuria in male mice suggests that this agent could be useful for improving renal function in males.
2-ME also inhibits serum-induced migration, proliferation, or collagen synthesis in cultured human and rat aortic vascular smooth muscle cells (VSMCs), cardiac fibroblasts, and glomerular mesangial cells. [25] [26] [27] [28] [29] Ang II produced renal fibrosis as indicated by increased interstitial α-smooth muscle actin and collagen accumulation in female Cyp1b1 −/− mice that had diminished 2-ME plasma and urinary levels. 15, 16 Our finding that administration of 2-ME abrogated these effects of Ang II in female Cyp1b1 −/− mice suggests that 2-ME also mediates the protective effect of estradiol against end-organ damage by Ang II. Supporting this conclusion is our observation that Ang II caused renal interstitial α-smooth muscle actin and collagen accumulation in OVX Cyp1b1 +/+ mice, but, as expected, OVX did not alter these effects of Ang II in Cyp1b1 −/− mice. Moreover, concurrent administration of 2-ME minimized Ang II-induced renal fibrosis in both OVX Cyp1b1 +/+ and Cyp1b1 −/− mice. In contrast, Ang II produced cardiac and renal fibrosis in Cyp1b1 +/+ male mice that were attenuated by Cyp1b1 gene deletion. 13, 14 Our finding that treatment with 2-ME also rescued the Cyp1b1 +/+ male mice from Ang II-induced cardiac and renal fibrosis indicates the potential use of this agent in treating cardiac fibrosis and end-organ damage not only in females with diminished estrogen levels but also in males with cardiac and renal disease.
Ang II is known to stimulate renal expression and urinary excretion of AGT in different hypertension models in male rats and contributes to increased renal production of Ang II, hypertension, renal dysfunction, and end-organ damage. [30] [31] [32] Sexual dimorphism exists in urinary excretion of AGT in Ang II-dependent hypertension and high-salt diet: males have a higher excretion of AGT and increased AGT mRNA expression compared with females. 31 In a previous study, we showed that Cyp1b1 gene disruption reduced Ang II-induced urinary excretion of AGT in male mice. 14 In this study, Ang II increased urinary excretion of AGT in intact Cyp1b1 genedisrupted or OVX female Cyp1b1 +/+ and Cyp1b1 −/− mice, and this increase in urinary excretion of AGT was attenuated in 2-ME-treated mice. These observations suggest that 2-ME most likely contributes to the protective effect of estradiol by reducing renal levels of AGT and confers protection against Ang II-induced hypertension, renal dysfunction, and endorgan damage in female mice. The mechanism by which 2-ME inhibits Ang II-induced urinary excretion of AGT in female mice remains to be determined. In male Cyp1b1 +/+ mice, Ang II increased urinary AGT excretion, but 2-ME failed to alter urinary levels of AGT; this result could be because of the opposing effect of the CYP1B1-testosterone-derived metabolite, 6β-hydroxytestosterone, that mediates Ang II-induced increase in urinary excretion of AGT in male mice. 14 In female mice, protection against Ang II-induced hypertension and renal dysfunction has been attributed to increased AT2:AT1 ratios and increased expression of ACE2 and Ang (1-7) production. 33, 34 2-ME in a rat liver epithelial cell line (WB cells) and VSMCs downregulated Ang II binding and AT1a receptor mRNA. 35 However, Cyp1b1 gene deletion that minimizes both the basal and Ang II-induced increase in plasma levels of 2-ME did not alter renal AT1a receptor or ACE expression in female mice. 16 In this study, ovariectomy or infusion of Ang II in OVX mice also did not alter renal mRNA expression of AT1a receptor or ACE. Furthermore, treatment with 2-ME in OVX or Cyp1b1 −/− female mice also failed to alter mRNA expression of AT1a receptor or ACE. Therefore, the protective effect of 2-ME against Ang II-induced changes in renal function seem to be independent of AT1A and ACE expression in the kidney.
The mechanism by which 2-ME modulates Ang II actions is not known. Estrogen, the precursor of 2-ME, produces its actions mainly via estrogen receptors acting as a transcriptional regulator. However, estrogen also exerts some actions, including inhibiting diastolic dysfunction and left ventricular remodeling caused by OVX in female mRen.Lewis rats via G protein-coupled receptor, namely GPER1. 36 A recent study showed that the balance between GPER1 and estrogen receptor regulates vascular remodeling. 37 GPER1 has also been implicated in 2-ME's reducing Ang II binding in the rat liver epithelial cell line. 34 However, GPER activation by 2-ME using luciferase assay has not been provided. Moreover, the effect of 2-ME to inhibit VSMC migration and proliferation and microglial cell BV2 proliferation and the process of phagocytosis were shown to be independent of estrogen or GPER1 receptors. 38 In our study in Cyp1b1 +/+ female mice, where Ang II increased plasma and urinary 2-ME levels, 15, 16 the selective GPER1 receptor antagonist G15 reduced heart:body weight ratio but failed to alter the effect of Ang II to increase SBP, heart:body weight ratio, water intake, or urine output. The decrease in heart weight produced by G15 is most likely because of a decrease in body weight. GPER1 agonist G1 has been reported to increase body weight and promotes adipogenesis. 39 However, G1 has been shown to exert actions independent of GPER1 in cancer and human VSMCs. 40, 41 Moreover, G1 like 2-ME produced VSMC arrest and apoptosis by tubular depolymerization. 42 These observations suggest that GPER1 is unlikely to mediate the effect of 2-ME or estradiol on the actions of Ang II in female mice. A recent study showed that 2-ME inhibits serum-induced VSMC migration and proliferation by blocking the RhoA/ ROCK1 pathway both by inhibiting the activation of RhoA and by reducing the expression of ROCK1 (rho-associated, coiled-coil-containing protein kinase 1). 43 Whether 2-ME mediates the effect of estradiol to protect against Ang II-induced hypertension, cardiac fibrosis, renal dysfunction, and end-organ damage in OVX and Cyp1b1 −/− female mice and in Cyp1b1 +/+ male mice by inhibiting the RhoA/ROCK1 pathway remains to be determined. Oxidative stress is known to contribute to Ang II-induced hypertension and its pathogenesis in various models of hypertension, including in Cyp1b1 −/− and OVX Cyp1b1 +/+ mice. 15, 16 Because 2-ME is a more potent antioxidant than is estradiol and inhibits free radical-induced proliferation and migration of VSMCs, 44, 45 it could also contribute to its protective effect against Ang II-induced hypertension, renal dysfunction, and end-organ damage in Cyp1b1 −/− and OVX Cyp1b1 +/+ female and Cyp1b1 +/+ male mice. In conclusion, this study provides evidence that the CYP1B1-estrogen-derived metabolite 2-ME protects against the actions of Ang II to increase thirst and produce cardiac fibrosis, proteinuria, end-organ damage, and AGT production in OVX and Cyp1b1 −/− female mice. In contrast, the testosterone metabolite generated by CYP1B1, 6β-hydroxytestosterone, plays a divergent role in males; it acts as a permissive factor and contributes to Ang II-induced hypertension and associated renal water and electrolyte dysfunction and end-organ damage.
14 Therefore, 2-ME could be used as a potential therapeutic agent for treating hypertension and associated renal dysfunction and end-organ damage in postmenopausal females and in intact males.
Perspectives
Sex differences in BP and renal dysfunction have been reported in humans and in various animal models of hypertension. Menopause increases the likelihood of developing hypertension and renal dysfunction in females. The present study provides further evidence for the beneficial effects of 2-ME for treating hypertension and associated renal dyshomeostasis and end-organ damage in postmenopausal females. This study also provides the first evidence that 2-ME could be useful for treating Ang II-induced hypertension and associated pathogenesis in males. More than 75% of woman older than 60 years are hypertensive in the United States. [46] [47] [48] Hormone replacement therapy in clinical trials have failed to lower BP or decrease cardiovascular diseases in postmenopausal females. [49] [50] [51] [52] [53] [54] Therefore, 2-ME could be useful in treating hypertension, renal dysfunction, and end-organ damage in postmenopausal females; hypoestrogenemic premenopausal women; women with menstrual irregularities because of ovarian failure; and in men. However, further studies are required to determine its clinical use in these conditions and to elucidate the mechanism by which 2-ME minimizes hypertension caused by Ang II and in other models of experimental hypertension and associated pathogenesis in females with diminished estrogen levels and in intact males.
